加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$15.01
+US$0.01 · +0.07%
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
常规交易时段
US$15.01
+US$0.01 · +0.07%
盘中时间采用ET。市场数据可能有所延迟。
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
日内区间
当前US$15.01
52周区间
当前US$15.01
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
59
合理估值
情绪
52
多空交织
风险
74
高风险
动量
28
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Headquartered in Guangzhou, China, and established in 2014, Burning Rock Biotech Limited is primarily engaged in developing and providing diagnostic solutions for cancer therapy selection within the People's Republic of China. Its operations are structured across three key segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company leverages next-generation sequencing (NGS) technology to offer a diverse portfolio of tests designed to guide therapeutic decisions and predict prognoses for a wide array of cancer types. These include, but are not limited to, lung, gastrointestinal, prostate, breast, lymphomas, thyroid, colorectal, ovarian, pancreatic, and bladder cancers. These analyses can be performed on both tissue and liquid biopsy samples. Burning Rock's flagship products encompass OncoCompass IO, a liquid biopsy test; OncoScreen IO, a comprehensive pan-cancer test for tissue samples; OncoCompass Target, a circulating tumor DNA (ctDNA) liquid biopsy-based test specifically for non-small cell lung cancer (NSCLC); ColonCore, which assesses microsatellite instability (MSI) and identifies genetic mutations relevant to gastrointestinal cancers; and the OncoScreen ParpMatch and OncoCompass ParpMatch tests, which target genes critical for homologous recombination deficiency. To further enhance its offerings, the company has entered into strategic agreements, including a development and commercialization license with Myriad Genetics, Inc. for Myriad myChoice tumor testing in China, and a licensing agreement with Oncocyte Corporation for DetermaRx, a risk stratification test for early-stage lung cancer patients, also for the Chinese market. Burning Rock also actively collaborates on clinical trials and research studies with a notable roster of pharmaceutical and biotech partners, such as AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, and Merck KGaA.
日内区间
当前US$15.01
52周区间
当前US$15.01
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（CNY） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 5.4亿 CNY | 5.16亿 CNY | 5.37亿 CNY | 5.63亿 CNY | 5.08亿 CNY |
| 销货成本 | 1.37亿 CNY | 1.53亿 CNY | 1.74亿 CNY | 1.83亿 CNY | 1.44亿 CNY |
| 毛利 | 4.03亿 CNY | 3.62亿 CNY | 3.63亿 CNY | 3.8亿 CNY | 3.64亿 CNY |
| 研究与开发 | 1.66亿 CNY | 2.32亿 CNY | 3.47亿 CNY | 4.22亿 CNY | 3.68亿 CNY |
| 销售、一般及管理费用 | 2.91亿 CNY | 4.53亿 CNY | 6.86亿 CNY | 9.39亿 CNY | 7.93亿 CNY |
| 营业费用 | 4.58亿 CNY | 7.2亿 CNY | 10.33亿 CNY | 13.6亿 CNY | 11.61亿 CNY |
| 利息收入 | 805.3万 CNY | 1221.2万 CNY | 1795.6万 CNY | 945.8万 CNY | 345.7万 CNY |
| 利息支出 | 3万 CNY | — | — | — | 153.6万 CNY |
| 折旧和摊销 | 2176.1万 CNY | 5220万 CNY | 1.33亿 CNY | 1.24亿 CNY | 4776.6万 CNY |
| 营业利润 | −5484.5万 CNY | −3.58亿 CNY | −6.69亿 CNY | −9.8亿 CNY | −7.97亿 CNY |
| 净利润 | −5534.6万 CNY | −3.47亿 CNY | −6.54亿 CNY | −9.71亿 CNY | −7.97亿 CNY |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅3项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年5月15日 | 1:10 | — | — |
股票拆分 | 2014年8月1日 | 1:3 | — | — |
已生效 2024年5月15日
1:10
已生效 2014年8月1日
1:3
报告持有此股票敞口的交易所交易基金。
Schwab International Equity ETFSCHF1906.77万0.03%673.48亿 USD0.03%US$27.095-0.13%
Schwab Fundamental International Large Company Index ETFFNDF1792.53万0.07%253.12亿 USD0.25%US$53.595+0.33%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1308.78万0.03%406.96亿 USD0.03%US$49.645-0.08%
State Street SPDR Portfolio Europe ETFSPEU35.23万0.05%6.89亿 USD0.07%US$53.225+0.39%
State Street SPDR MSCI EAFE StrategicFactors ETFQEFA25.9万0.03%10.17亿 USD0.30%US$98.02+0.51%
State Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAX20.23万0.04%4.88亿 USD0.20%US$53.25+0.24%
State Street SPDR MSCI World StrategicFactors ETFQWLD1.45万0.01%1.76亿 USD0.30%US$156.680.00%Schwab International Equity ETFSCHFSchwab Fundamental International Large Company Index ETFFNDFState Street SPDR Portfolio Developed World ex-US ETFSPDWState Street SPDR Portfolio Europe ETFSPEUState Street SPDR MSCI EAFE StrategicFactors ETFQEFAState Street SPDR MSCI EAFE Fossil Fuel Reserves Free ETFEFAXState Street SPDR MSCI World StrategicFactors ETFQWLDAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
